DER Reference Model Version 1.0.0
ecqm.measure

CMS52v7 - HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis

Rationale:

HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis. Although advances in the management of HIV and AIDS diseases have been made, Pneumocystis jiroveci pneumonia (PCP) remains an important complication and cause of morbidity. Without PCP prophylaxis, patients with HIV/AIDS are at increased risk of developing PCP, especially when CD4 cell counts falls to 200 cells/mm3-250 cells/mm3 (Kaplan, 1998; Phair, 1990). PCP prophylaxis is very effective and has been demonstrated to prolong life. Data from Kaiser Permanente suggests that there is a gap in care related to the prescription of PCP prophylaxis for patients with HIV. According to 2005-2006 data from Kaiser Permanente California (both Northern and Southern), Georgia, and Oregon, only 71% of HIV-infected persons with a CD4<200 cells/mm3 received PCP prophylaxis (personal communication, 2007).